EP1263775A4 - Peptides de liaison hla et utilisations de ces derniers - Google Patents

Peptides de liaison hla et utilisations de ces derniers

Info

Publication number
EP1263775A4
EP1263775A4 EP00910314A EP00910314A EP1263775A4 EP 1263775 A4 EP1263775 A4 EP 1263775A4 EP 00910314 A EP00910314 A EP 00910314A EP 00910314 A EP00910314 A EP 00910314A EP 1263775 A4 EP1263775 A4 EP 1263775A4
Authority
EP
European Patent Office
Prior art keywords
binding peptides
hla binding
hla
peptides
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00910314A
Other languages
German (de)
English (en)
Other versions
EP1263775A1 (fr
Inventor
Alessandro Sette
John Sidney
W Martin Kast
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1263775A1 publication Critical patent/EP1263775A1/fr
Publication of EP1263775A4 publication Critical patent/EP1263775A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00910314A 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers Withdrawn EP1263775A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/004655 WO2001062776A1 (fr) 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers

Publications (2)

Publication Number Publication Date
EP1263775A1 EP1263775A1 (fr) 2002-12-11
EP1263775A4 true EP1263775A4 (fr) 2004-10-06

Family

ID=21741082

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00910314A Withdrawn EP1263775A4 (fr) 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers

Country Status (8)

Country Link
EP (1) EP1263775A4 (fr)
JP (1) JP2003524016A (fr)
CN (1) CN1452634A (fr)
AU (1) AU2000232427A1 (fr)
BR (1) BR0017136A (fr)
CA (1) CA2400215A1 (fr)
MX (1) MXPA02008219A (fr)
WO (1) WO2001062776A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1917970B1 (fr) * 1999-06-29 2011-06-15 Epimmune Inc. Peptides se fixant au Hla et leurs utilisations
AU2001242190A1 (en) * 2000-03-31 2001-10-15 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
AU2005265182B2 (en) 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
EP2333060B1 (fr) * 2005-01-25 2016-05-25 NEC Corporation Peptides se liant au HLA, fragments d'ADN codant pour lesdits peptides et vecteurs recombinants
AU2006259307B2 (en) 2005-06-17 2012-12-20 Mannkind Corporation Epitope analogues
KR20080026181A (ko) * 2005-06-17 2008-03-24 맨카인드 코포레이션 암세포 및 종양 기질에 발현된 우성 및 준우성 에피토프에대한 다가 면역반응을 유발하기 위한 방법 및 조성물
CN1948333B (zh) * 2005-10-14 2010-12-08 中国人民解放军第二军医大学 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
US7632814B2 (en) * 2006-09-07 2009-12-15 University Of South Florida HYD1 peptides as anti-cancer agents
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
WO2011115688A2 (fr) 2010-03-19 2011-09-22 H. Lee Moffitt Cancer Center & Research Institute Inhibiteurs des interactions de l'intégrine pour traiter le cancer
US20130183376A1 (en) * 2010-09-08 2013-07-18 Saitama Medical University Hepatitis c virus liposome vaccine
WO2015048477A1 (fr) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugués de peptide cyclique et procédés d'utilisation
WO2018065628A2 (fr) 2016-10-07 2018-04-12 Enterome Variants de séquence de microbiote d'épitopes antigéniques associés à une tumeur
AU2017339577B2 (en) 2016-10-07 2021-12-02 Enterome S.A. Immunogenic compounds for cancer therapy
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
AU2017367642A1 (en) 2016-11-30 2019-05-30 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CA3081710A1 (fr) * 2017-11-08 2019-05-16 Advaxis, Inc. Peptides heteroclitiques immunogenes issus de proteines associees au cancer et procedes d'utilisation de ces peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (fr) * 1993-03-05 1994-09-15 Cytel Corporation Peptides se liant a hla-a2.1 et leurs utilisations
WO1997034621A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de fixation de hla-a2.1 et leurs utilisations
WO1998004284A1 (fr) * 1996-07-25 1998-02-05 The Johns Hopkins University Nouveaux genes de l'herpesvirus associe a la maladie de kaposi

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (fr) * 1993-03-05 1994-09-15 Cytel Corporation Peptides se liant a hla-a2.1 et leurs utilisations
WO1997034621A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de fixation de hla-a2.1 et leurs utilisations
WO1998004284A1 (fr) * 1996-07-25 1998-02-05 The Johns Hopkins University Nouveaux genes de l'herpesvirus associe a la maladie de kaposi

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NAYERSINA R ET AL: "HLA A2 RESTRICTED CYTOTOXIC T LYMPHOCYTE RESPONSES TO MULTIPLE HEPATITIS B SURFACE ANTIGEN EPITOPES DURING HEPATITIS B VIRUS INFECTION", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 150, no. 10, 15 May 1993 (1993-05-15), pages 4659 - 4671, XP000609159, ISSN: 0022-1767 *
NIJMAN H W: "IDENTIFICATION OF PEPTIDE SEQUENCES THAT POTENTIALLY TRIGGER HLA-A2.1-RESTRICTED CYTOTOXIC T LYMPHOCYTES", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 23, 1 June 1993 (1993-06-01), pages 1215 - 1219, XP000674255, ISSN: 0014-2980 *
See also references of WO0162776A1 *
SETTE A ET AL: "PEPTIDE BINDING TO THE MOST FREQUENT HLA-A CLASS I ALLELES MEASURED BY QUANTITATIVE MOLECULAR BINDING ASSAYS", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 31, no. 11, 1994, pages 813 - 822, XP000603774, ISSN: 0161-5890 *

Also Published As

Publication number Publication date
WO2001062776A1 (fr) 2001-08-30
AU2000232427A1 (en) 2001-09-03
CA2400215A1 (fr) 2001-08-30
CN1452634A (zh) 2003-10-29
EP1263775A1 (fr) 2002-12-11
MXPA02008219A (es) 2005-06-30
JP2003524016A (ja) 2003-08-12
BR0017136A (pt) 2003-02-25

Similar Documents

Publication Publication Date Title
EP1578432A4 (fr) Peptides de liaison hla et utilisations de ces derniers
AU2001288301A1 (en) Binding polypeptides and methods based thereon
EP1263775A4 (fr) Peptides de liaison hla et utilisations de ces derniers
AU9667901A (en) Mycoattractants and mycopesticides
GB2359863B (en) Turbocharger
GB2362604B (en) Book cover and book binding system using the book cover
EP1414848A4 (fr) Les peptides "replikines" et leurs utilisations
EP1419175A4 (fr) Peptides de replikine et leur utilisation
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
EP1343819A4 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
GB0026134D0 (en) Peptides and their use
GB2364273B (en) Book covering
AU2003285892A8 (en) Bace binding peptides and uses thereof
EP1313505A4 (fr) Peptides de fixation de hla et leurs utilisations
EP1337543A4 (fr) Peptides de liaison a la streptavidine et leurs utilisations
GB0001825D0 (en) Peptides
GB0020952D0 (en) Genes and proteins and their uses
AU5368201A (en) Mre11 orthologue and uses thereof
GB0007263D0 (en) Peptides
EP1071434A4 (fr) Facteurs de liaison cnre et utilisations correspondantes
GB0026136D0 (en) Peptides and their use
GB0026135D0 (en) Peptides and their use
GB0018148D0 (en) Peptides and their use
GB0019503D0 (en) Proteins and their uses
SG10201403662QA (en) Replikin peptides and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040819

17Q First examination report despatched

Effective date: 20070213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070824